{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.8","upperLimit":"41.6","value":"30.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"description":"CR + CRh rate by initiation of Cycle 2 is defined as the percentage of participants who achieved CR or CRh by initiation of Cycle 2 of study treatment.\n\nCR: ANC ≥ 10\\^3 /µL, platelet counts ≥ 10\\^5 /µL, RBC transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \\< 5% blasts.\n\nCRh is a derived response based on bone marrow blast and hematology lab values. A participant achieved a CRh when meeting the following criteria:\n\n* Bone marrow with \\< 5% blasts and\n* Peripheral blood neutrophil count of \\> 0.5 × 10\\^3 /µL and\n* Peripheral blood platelet count of \\> 0.5 × 10\\^5 /µL and\n* A 1 week (≥ 7 days) platelet transfusion-free period prior to the hematology lab collection.\n\nParticipants who never achieved CR/CRh or did not have disease assessment by initiation of Cycle 2 were considered to be non-responders in the calculation of CR + CRh rate by initiation of Cycle 2.","dispersionType":"95% Confidence Interval","groups":[{"description":"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 50 mg, and increased up to 600 mg by Day 6. Beginning with Cycle 2, 600 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received LDAC (20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.\n\nParticipants could continue receiving treatment until disease progression or until discontinuation criteria were met.","id":"OG000","title":"Phase 1+2: 600 mg Venetoclax + LDAC"}],"paramType":"NUMBER","populationDescription":"All enrolled participants who received venetoclax with LDAC at the recommended Phase 2 dose (600 mg)","reportingStatus":"POSTED","timeFrame":"Cycle 2, Day 1","title":"CR Plus CRh Rate by Initiation of Cycle 2","type":"SECONDARY","unitOfMeasure":"percentage of participants"}